StockNews.com assumed coverage on shares of Delcath Systems (NASDAQ:DCTH – Get Rating) in a research report issued on Monday. The firm set a “sell” rating on the stock.
Other equities research analysts have also issued research reports about the stock. BTIG Research dropped their price objective on shares of Delcath Systems to $19.00 in a report on Tuesday, November 15th. Canaccord Genuity Group dropped their price objective on shares of Delcath Systems from $17.00 to $14.00 in a report on Monday, November 21st.
Delcath Systems Stock Down 0.6 %
Shares of NASDAQ DCTH opened at $4.71 on Monday. The firm has a 50-day simple moving average of $4.27 and a 200-day simple moving average of $3.64. The stock has a market capitalization of $47.34 million, a price-to-earnings ratio of -1.24 and a beta of 0.87. Delcath Systems has a 52 week low of $2.34 and a 52 week high of $6.82.
Insiders Place Their Bets
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Delcath Systems in the second quarter valued at approximately $40,000. Vanguard Group Inc. raised its holdings in Delcath Systems by 5.7% during the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after purchasing an additional 19,605 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Delcath Systems during the first quarter worth approximately $75,000. Finally, Cibc World Market Inc. raised its holdings in Delcath Systems by 4.0% during the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after purchasing an additional 3,432 shares in the last quarter. Hedge funds and other institutional investors own 25.66% of the company’s stock.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.